Muir-Torre syndrome
Muir-Torre Syndrome (MTS) is a subtype of Lynch syndrome. It is an inherited condition that increases a person’s lifetime risk for developing rare types of skin, colorectal, and genitourinary tract cancers.
Muir-Torre Syndrome (MTS) is a subtype of Lynch syndrome. It is an inherited condition that increases a person’s lifetime risk for developing rare types of skin, colorectal, and genitourinary tract cancers.
The MLH1 and MSH2 genes are most commonly mutated in MTS patients.
The presence of specific types of skin or internal cancers are the primary symptoms of MTS.
Skin Cancers
Since MTS is a subtype of Lynch syndrome, the diagnosis, risk factors, and treatment of this disorder is very similar.
Watch videos of two major general sessions from AllyCon 2024, the Alliance's patient support conference, which took place in Miami Beach in December.
Learn how the Colorectal Cancer Alliance is advocating for the passage of the Nancy Gardner Sewell Multi-Cancer Early Detection Act (HR 2407), a bipartisan bill that ensures immediate Medicare coverage for life-saving cancer detection tests once approved by the FDA.
The treatment option is for patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC) who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.